# Adicet Bio, Inc.: overview ACET · Nasdaq · CIK 1720580 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 26 Pages: [Overview](/companies/acet.md) · [Financials](/companies/acet/financials.md) · [Filings](/companies/acet/filings.md) · [Insiders](/companies/acet/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.34)](/filings/0001193125-25-266880.md) | not reported | [(4.96)](/filings/0001720580-26-000037.md) | [(5.48)](/filings/0001720580-26-000050.md) | [(0.29)](/filings/0001193125-25-266880.md) | not reported | [(1.88)](/filings/0001720580-26-000037.md) | [(1.99)](/filings/0001720580-26-000050.md) | | Free cash flow | $m | [(22.4) d](/filings/0001193125-25-266880.md) | [(24.3) d](/filings/0001720580-26-000008.md) | [(26.9)](/filings/0001720580-26-000037.md) | [(26.7) d](/filings/0001720580-26-000050.md) | [(22.5) d](/filings/0001193125-25-266880.md) | [(20.9) d](/filings/0001720580-26-000008.md) | [(21.5)](/filings/0001720580-26-000037.md) | [(20.0) d](/filings/0001720580-26-000050.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.00)](/filings/0000950170-23-008130.md) | [(1.70)](/filings/0000950170-24-033482.md) | [(3.31)](/filings/0000950170-25-034587.md) | [(21.33)](/filings/0001720580-26-000008.md) | [(16.95)](/filings/0001720580-26-000008.md) | | Free cash flow | $m | [(64.1)](/filings/0000950170-23-008130.md) | [(61.5)](/filings/0000950170-24-033482.md) | [(98.2)](/filings/0000950170-25-034587.md) | [(93.5)](/filings/0001720580-26-000008.md) | [(97.0)](/filings/0001720580-26-000008.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/acet/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $8.1m | 932,624 | | Reduced −250,000 | | [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $7.3m | 844,787 | | Reduced −183,157 | | [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $5.4m | 626,571 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $3.7m | 432,738 | | Added +50,915 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $3.0m | 343,228 | | Added +6,704 | | [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $2.4m | 274,375 | | Unchanged | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $2.3m | 265,945 | | Added +33,354 | | [Stonepine Capital Management, LLC](/funds/1440771.md) | 2026-06-30 | $2.1m | 245,518 | | Added +23,563 | | [Alyeska Investment Group, L.P.](/funds/1453072.md) | 2026-06-30 | $1.8m | 203,799 | | Unchanged | | [Schonfeld Strategic Advisors LLC](/funds/1665241.md) | 2026-06-30 | $1.7m | 195,514 | | New +195,514 | ## Recent filings [All 667 filings](/companies/acet/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-28 | 08:15 ET | [8-K](/filings/0001720580-26-000060.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001720580-26-000060 | | 2026-09-08 | 16:17 ET | [8-K](/filings/0001720580-26-000056.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001720580-26-000056 | | 2026-09-01 | 07:02 ET | [8-K](/filings/0001720580-26-000054.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001720580-26-000054 | | 2026-08-05 | 16:21 ET | [10-Q](/filings/0001720580-26-000050.md) | Quarterly report, period 2026-06-30 | 0001720580-26-000050 | | 2026-08-05 | 16:18 ET | [8-K](/filings/0001720580-26-000049.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001720580-26-000049 | | 2026-06-18 | 16:01 ET | [8-K](/filings/0001720580-26-000043.md) | 5.07 Shareholder vote results | 0001720580-26-000043 | | 2026-05-20 | 16:10 ET | [10-K/A](/filings/0001720580-26-000042.md) | Annual report, amended, period 2025-12-31 | 0001720580-26-000042 | | 2026-05-13 | 16:32 ET | [10-Q](/filings/0001720580-26-000037.md) | Quarterly report, period 2026-03-31 | 0001720580-26-000037 | | 2026-05-13 | 16:04 ET | [8-K](/filings/0001720580-26-000036.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001720580-26-000036 | | 2026-04-29 | 16:02 ET | [DEF 14A](/filings/0001720580-26-000027.md) | Proxy statement, period 2026-04-29 | 0001720580-26-000027 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001720580-26-000008.md), filed Mar 12, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1720580 - Tickers: ACET - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.